NCCN Guidelines® Insights: Biliary Tract Cancers, Version 2.2023
Novartis (Switzerland) · Amgen (United States) · +65 more institutions
Abstract
In 2023, the NCCN Guidelines for Hepatobiliary Cancers were divided into 2 separate guidelines: Hepatocellular Carcinoma and Biliary Tract Cancers. The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts meets at least on an annual basis to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on…
Citation impact
- FWCI
- 60.91
- Percentile
- 100%
- References
- 35
Authors
41- ABAl B. BensonCorresponding
Novartis (Switzerland), Amgen (United States), Janssen (Belgium), Bristol-Myers Squibb (Germany), Pfizer (United Kingdom), AbbVie (United States), Boston Scientific (United States), Astellas Pharma (China), GlaxoSmithKline (India), FitBionic (United States), Array BioPharma (United States), Mirati Therapeutics (United States), Infinity Pharmaceuticals (United States), Samsung (United Kingdom), Apexigen (United States), Taiho Pharmaceutical (Japan), Taiho Oncology (United States), Robert H. Lurie Comprehensive Cancer Center of Northwestern University
- MIMichael I. D’Angelica
Memorial Sloan Kettering Cancer Center
- TAThomas A. Abrams
Dana-Farber Brigham Cancer Center
- DEDaniel E. Abbott
University of Wisconsin Carbone Cancer Center
- AAAijaz Ahmed
Cancer Institute (WIA), Stanford Cancer Institute
Topics & keywords
- Medicine
- Biliary tract cancer
- Biliary tract
- Intrahepatic Cholangiocarcinoma
- Gallbladder cancer
- Gallbladder
- Internal medicine
- Cancer
- Good health and well-being